Elevated serum levels of the apoptosis related molecules TNF-α, Fas/Apo-1 and Bcl-2 in oral lichen planus

Journal of Oral Pathology and Medicine

Volumn 33, Issue 7, 2004, Pages 386-390

  Sklavounou Andrikopoulou, Alexandra ^a,d   Chrysomali, E ^a   Iakovou, M ^a   Garinis, G A ^b   Karameris, A ^c  

^a UNIVERSITY OF ATHENS   (Greece)

^b MEDICANALYSIS   (Greece)

^c Veterans Administration Hospital NIMTS   (Greece)

^d NONE   (Greece)

Author keywords

Apoptosis; Bcl 2; Fas Apo 1; Lichen planus; Mouth; Serum levels; Tumor necrosis factor

Indexed keywords

FAS ANTIGEN; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LICHEN PLANUS; MALE; MOUTH LICHEN PLANUS; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; STATISTICAL SIGNIFICANCE;

ANTIGENS, CD95; APOPTOSIS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LICHEN PLANUS, ORAL; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3342945136     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2004.00221.x     Document Type: Article

References (35)

1. Teraki Y, Shiohara T. Apoptosis and the skin. Eur J Dermatol 1999; 9: 413-26.
2. Vassali P. The pathophysiology of tumor necrosis factor. Annu Rev Immunol 1992; 10: 411-52.
3. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314-17.
4. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76: 969-76.
5. Lynch DH, Watson ML, Alderson MR, et al. The mouse Fas-ligand gene is mutated in gld mice and in part of the TNF family gene cluster. Immunity 1994; 1: 131-36.
6. Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759-62.
7. Bagán Sebastian JV, Milian Masanet MA, Peñarrocha Diago M, Jimenez Y. A clinical study of 205 patients with oral lichen planus. J Oral Maxillofac Surg 1992; 50: 116-8.
8. Yamamoto T, Yoneda K, Ueta E, Osaki T. Cellular immunosuppression in oral lichen planus. J Oral Pathol Med 1990; 19: 464-70.
9. Walsh LJ, Savage NW, Ishii T, Seymour GJ. Immunopathogenesis of oral lichen planus. J Oral Pathol Med 1990; 19: 389-96.
10. Sugerman PB, Savage NW, Walsh LJ, et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med 2002; 13: 350-65.
11. Dekker NP, Lozada-Nur F, Lagenaur LA, MacPhail LA, Bloom CY, Regezi JA. Apoptosis-associated markers in oral lichen planus. J Oral Pathol Med 1997; 26: 170-5.
12. Bloor BK, Malik FK, Odell EW, Morgan PR. Quantitative assessment of apoptosis in oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 88: 187-95.
13. Majorana A, Facchetti F, Pelligrini W, Sapelli P. Apoptosis-associated markers in oral lichen planus. J Oral Pathol Med 1999; 28: 47-8.
14. Sklavounou A, Chrysomali E, Scorilas A, Karameris A. TNF-α expression and apoptosis-regulating proteins in oral lichen planus: a comparative immunohistochemical evaluation. J Oral Pathol Med 2000; 29: 370-75.
15. Neppelberg E, Johannessen AC, Jonsson R. Apoptosis in oral lichen planus. Eur J Oral Sci 2001; 109: 361-64.
16. Khan A, Farah CS, Savage NW, Walsh LJ, Harbrow DJ, Sugerman PB. Th1 cytokines in oral lichen planus. J Oral Pathol Med 2003; 32: 77-83.
17. Karatsaidis A, Schreurs O, Helgeland K, Axéll T, Schenck K. Erythematous and reticular forms of oral lichen planus and oral lichenoid reactions differ in pathological features related to disease activity. J Oral Pathol Med 2003; 32: 275-81.
18. Porter SR, Kirby A, Olsen I, Barret W. Immunologic aspects of dermal and oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 83: 358-66.
19. Rodríguez-Nuñez I, Blanco-Carrión A, García AG, Rey JG. Peripheral T-cell subsets in patients with reticular and atrophic-erosive oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 91: 180-8.
20. Yamamoto T, Yoneda K, Ueta E, Osaki T. Serum cytokines, interleukin-2 receptor, and soluble intercellular adhesion molecule-1 in oral disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1994; 78: 727-35.
21. Miklos S, Gruschwitz MS. In situ expression and serum levels of tumor necrosis factor alpha receptors in patients with lichen planus. Ada Derm Venereol 1997; 77: 191-193.
22. Karagouni EE, Dotsika EN, Sklavounou A. Alteration in peripheral blood mononuclear cell function and serum cytokines in oral lichen planus. J Oral Pathol Med 1994; 23: 28-35.
23. Jodo S, Kobayashi S, Kayagaki N, et al. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol 1997; 107: 89-95.
24. Miret C, Font J, Molina R, et al. Bcl-2 oncogene (B cell lymphoma/leukemia-2) levels correlate with systemic lupus erythematosus disease activity. Anticancer Res 1999; 19: 3073-76.
25. Kramer IR, Lucas RB, Pindborg JJ, Sobin LH. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol 1978; 46: 518-39.
26. Sugerman PB, Rollason PA, Savage NW, et al. Suppressor cell function in oral lichen planus. J Dent Res 1992; 71: 1916-19.
27. Tomokuni A, Aikoh T, Matsuki T, et al. Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumors. Clin Exp Immunol 1997; 110: 303-9.
28. Midis GP, Shen Y, Owen-Schaub LB. Elevated soluble Fas (sFas) levels in nonhaematopoietic human malignancy. Cancer Res 1996; 56: 3870-4.
29. Fujihara T, Takeuchi T, Tsubota K, et al. Serum soluble Fas/APO-1 is increased in patients with primary Sjögren's syndrome. Clin Rheumatol 1998; 17: 496-9.
30. Hamzaoui K, Hamzaoui A, Zakraoui L, Chabbou A. Levels of soluble Fas/Apo-1 in patients with Behcet's disease. Mediators Inflamm 1998; 7: 111-4.
31. Sakai T, Inoue A, Koh CS, Osame M. Serum levels of apoptosis-related molecules in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy. J Interferon Cytokine Res 1999; 19: 999-1004.
32. Miret C, Font J, Molina R, et al. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus. Anticancer Res 2001; 21: 3053-9.
33. Sugerman PB, Satterwhite K, Bigby M. Auto-cytotoxic T cell clones in lichen planus. Br J Dermatol 2000; 142: 449-56.
34. Torre D, Zeroli C, Speranza F, Martegani R, Fiori G, Airoldi M. Serum levels of Fas/Apo-1 and Bcl-2 in children with HIV-1 infection. Scand J Infect Dis 1998; 30: 565-8.
35. Sugerman PB, Savage NW, Seymour GJ. Phenotype and suppressor activity of T lymphocyte clones extracted from lesions of oral lichen planus. Br J Dermatol 1994; 131: 319-24.